(A) Duration of response and (B) time to treatment failure. Duration of response was defined as the duration of platelet count ≥50 × 109/L in 2 consecutive blood samples taken at least 24 hours apart, without having received any platelet-elevating therapy or having had dose increment of TPO-RA and/or corticosteroids, and starting from a minimum of 4 weeks following the last daratumumab injection. Loss of response was defined as platelet count <50 × 109/L after achieving response, in 2 consecutive blood samples taken at least 24 hours apart. Time to treatment failure was defined as a time with platelet count ≥50 × 109/L from 4 weeks after the last daratumumab injection to the first platelet count <30 × 109/L of 2 counts taken in 2 consecutive measurements at least 24 hours apart, or administration of any platelet-elevating therapy after achieving response.
